Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ONKT106
- Development stage
- Preclinical
- Lead developer
- ONK Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
ONKT106 is an investigational, engineered natural killer (NK) cell therapy developed by ONK Therapeutics. This therapy involves gene-editing NK cells to enhance their cytotoxic potential, metabolic health, and persistence within the tumor microenvironment. Specifically, ONKT106 utilizes CISH (Cytokine-inducible SH2-containing protein) knockout technology, licensed from WEHI, to improve NK cell function. It is being developed for the treatment of various cancers, including blood cancers such as multiple myeloma and acute myeloid leukemia (AML), as well as solid tumors like ovarian, breast, and non-small cell lung cancer (NSCLC).
02
Targets
CD96 (T-cell surface protein tactile)CISH (Cytokine-inducible SH2-containing protein)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TNFRSF10A (Death receptor 4)TNFRSF10B (DR5)LAG3 (Lymphocyte activation Gene-3 protein)PDCD1 (Programmed cell death protein 1 receptor)SIGLEC7 (Sialic acid-binding Ig-like lectin 7)SIGLEC9 (Sialic acid-binding immunoglobulin-like lectin 9)TGFBR2 (TGF-β receptor type 2)TIGIT (T cell immunoreceptor with Ig and ITIM domains)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)
Beyond the preview
Go deeper on ONKT106.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONKT106.